FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background: Lung cancer has emerged as one of the most common cancers in recent years. The mitochondrial electron transport chain (ETC) is closely connected with metabolic pathways and inflammatory response. However, the influence of ETC-associated genes on the tumor immune response and the pathogenesis of lung cancer is not clear and needs further exploration. Methods: The RNA-sequencing transcriptome and clinical characteristic data of LUAD were downloaded from the Cancer Genome Atlas (TCGA) database. The LASSO algorithm was used to build the risk signature, and the prediction model was evaluated by the survival analysis and receiver operating characteristic curve. We explored the function of FDX1 through flow cytometry, molecular biological methods, and liquid chromatography–tandem mass spectrometry/mass spectrometry (LC–MS/MS). Results: 12 genes (FDX1, FDX2, LOXL2, ASPH, GLRX2, ALDH2, CYCS, AKR1A1, MAOB, RDH16, CYBB, and CYB5A) were selected to build the risk signature, and the risk score was calculated with the coefficients from the LASSO algorithm. The 1-year, 3-year, and 5-year area under the curve (AUC) of ROC curves of the dataset were 0.7, 0.674, and 0.692, respectively. Univariate Cox analysis and multivariate Cox regression analysis indicated that the risk signature is an independent risk factor for LUAD patients. Among these genes, we focused on the FDX1 gene, and we found that knockdown of FDX1 neither inhibited tumor cell growth nor did it induce apoptosis or abnormal cell cycle distribution. But FDX1 could promote the ATP production. Furthermore, our study showed that FDX1 was closely related to the glucose metabolism, fatty acid oxidation, and amino acid metabolism. Conclusion: Collectively, this study provides new clues about carcinogenesis induced by ETC-associated genes in LUAD and paves the way for finding potential targets of LUAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Understanding the Intersections between Metabolism and Cancer Biology
Vander Heiden, M. G., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,293
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Duma, N., Santana-Davila, R., & Molina, J. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.013 · Cited by 2,184
Non-small cell lung cancer: current treatment and future advances
Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944
Global Epidemiology of Lung Cancer
Barta, J. A., Powell, C. A., & Wisnivesky, J. P. (2019) · Annals of Global Health · doi:10.5334/aogh.2419 · Cited by 1,575
Metabolic pathways promoting cancer cell survival and growth
Boroughs, L. K., & DeBerardinis, R. J. (2015) · Nature Cell Biology · doi:10.1038/ncb3124 · Cited by 1,462
Metabolic heterogeneity in human lung tumors
Hensley, C. T., Faubert, B., Yuan, Q., Lev-Cohain, N., Jin, E., Kim, J., Jiang, L., Ko, B., Skelton, R., Loudat, L., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.034 · Cited by 1,138
Metabolic Reprogramming of Immune Cells in Cancer Progression
Biswas, S. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.001 · Cited by 721 · cited 1×
“Metabolism plays an important role in carcinogenesis, and in recent years, it has been leveraged for tumor treatments (Biswas, 2015; Vander Heiden and DeBerardinis, 2017; Kumar and Misra, 2019).”
BackgroundMitochondrial metabolism promotes adaptation to proteotoxic stress
Tsvetkov, P., Detappe, A., Cai, K., Keys, H. R., Brune, Z., Ying, W., Thiru, P., Reidy, M., Kugener, G., Rossen, J., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0291-9 · Cited by 645
Huang, J., Liu, D., Wang, Y., Liu, L., Li, J., Yuan, J., Jiang, Z., Jiang, Z., Hsiao, W. W., Liu, H., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-321031 · Cited by 539
Sher, T., Dy, G. K., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.355 · Cited by 498
The organization and inheritance of the mitochondrial genome
Chen, X. J., & Butow, R. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1708 · Cited by 479
Sheftel, A. D., Stehling, O., Pierik, A. J., Elsässer, H.-P., Mühlenhoff, U., Webert, H., Hobler, A., Hannemann, F., Bernhardt, R., & Lill, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004250107 · Cited by 406
Metabolic Pathways Regulating Colorectal Cancer Initiation and Progression
La Vecchia, S., & Sebastián, C. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.018 · Cited by 349
Structural basis for pregnenolone biosynthesis by the mitochondrial monooxygenase system
Strushkevich, N., MacKenzie, F., Cherkesova, T., Grabovec, I., Usanov, S., & Park, H.-W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019441108 · Cited by 337
Mitochondrial DNA variation and cancer
Kopinski, P. K., Singh, L. N., Zhang, S., Lott, M. T., & Wallace, D. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00358-w · Cited by 301
Bustamante, J., Arias, A. A., Vogt, G., Picard, C., Galicia, L. B., Prando, C., Grant, A. V., Marchal, C. C., Hubeau, M., Chapgier, A., et al. (2011) · Nature Immunology · doi:10.1038/ni.1992 · Cited by 287
Spectrum of somatic mitochondrial mutations in five cancers
Larman, T. C., DePalma, S. R., Hadjipanayis, A. G., The Cancer Genome Atlas Research Network, Protopopov, A., Zhang, J., Gabriel, S. B., Chin, L., Seidman, C. E., Kucherlapati, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211502109 · Cited by 240
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells
Chen, P.-H., Cai, L., Huffman, K., Yang, C., Kim, J., Faubert, B., Boroughs, L., Ko, B., Sudderth, J., McMillan, E. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.028 · Cited by 212
Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality.
Heron, M. P., & Anderson, R. N. (2016) · PubMed · Cited by 203
Shi, Y., Ghosh, M., Kovtunovych, G., Crooks, D. R., & Rouault, T. A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.11.002 · Cited by 194
Cancer stem cell metabolism: target for cancer therapy
Chae, Y. C., & Kim, J. H. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.7.112 · Cited by 184
Cancer metabolomic markers in urine: evidence, techniques and recommendations
Dinges, S. S., Hohm, A., Vandergrift, L. A., Nowak, J., Habbel, P., Kaltashov, I. A., & Cheng, L. L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0185-3 · Cited by 161
Kang, Y. J., Bang, B.-R., Han, K. H., Hong, L., Shim, E.-J., Ma, J., Lerner, R. A., & Otsuka, M. (2015) · Nature Communications · doi:10.1038/ncomms9371 · Cited by 144
Glutamine Addiction and Therapeutic Strategies in Lung Cancer
Vanhove, K., Derveaux, E., Graulus, G., Mesotten, L., Thomeer, M., Noben, J., Guedens, W., & Adriaensens, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020252 · Cited by 143
Bi, K., Wei, X.-G., Qin, X., & Li, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00424 · Cited by 132
Ince, M. N., de la Monte, S. M., & Wands, J. R. (2000) · PubMed · Cited by 129
Garon, E. B., Christofk, H. R., Hosmer, W., Britten, C. D., Bahng, A. Y., Crabtree, M., Hong, C. S., Kamranpour, N., Pitts, S. L., Kabbinavar, F. F., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1583-9 · Cited by 127
Challenges and Opportunities in Cancer Metabolomics
Kumar, A., & Misra, B. B. (2019) · PROTEOMICS · doi:10.1002/pmic.201900042 · Cited by 118
Aspartate β-hydroxylase as a target for cancer therapy
Kanwal, M., Šmahel, M., Olsen, M. J., Šmahelová, J., & Tachezy, R. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01669-w · Cited by 87
ALDH2 Repression Promotes Lung Tumor Progression via Accumulated Acetaldehyde and DNA Damage
Li, K., Guo, W., Li, Z., Wang, Y., Sun, B., Xu, D., Jing, L., Song, H., Liao, Y., Wang, T., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.03.008 · Cited by 77
Zhang, Y., Yang, M., Ng, D. M., Haleem, M., Yi, T., Hu, S., Zhu, H., Zhao, G., & Liao, Q. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.024 · Cited by 77
Fatty acid oxidation: driver of lymph node metastasis
Li, M., Xian, H.-C., Tang, Y.-J., Liang, X., & Tang, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02057-w · Cited by 68
Liu, X., Lu, Y., Chen, Z., Liu, X., Hu, W., Zheng, L., Chen, Y., Kurie, J. M., Shi, M., Mustachio, L. M., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0579 · Cited by 65
Mitochondrial Control of Genomic Instability in Cancer
Bonora, M., Missiroli, S., Perrone, M., Fiorica, F., Pinton, P., & Giorgi, C. (2021) · Cancers · doi:10.3390/cancers13081914 · Cited by 46
Kimura, M., Yasue, F., Usami, E., Kawachi, S., Iwai, M., Go, M., Ikeda, Y., & Yoshimura, T. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1640 · Cited by 27
Wang, S., Wu, C., Ma, D., & Hu, Q. (2021) · PeerJ · doi:10.7717/peerj.11233 · Cited by 25
Inhibition of human natural killer cell functional activity by human aspartyl β-hydroxylase
Huyan, T., Li, Q., Ye, L.-J., Yang, H., Xue, X.-P., Zhang, M.-J., Huang, Q., Yin, D., & Shang, P. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.09.018 · Cited by 17
PFKP phenotype in lung cancer: prognostic potential and beyond
Ganapathy‐Kanniappan, S. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05805-9 · Cited by 12 · cited 1×
“A recent research work has shown that D-fructose 6-phosphate associated with PFKP may be a prognostic factor for lung cancer (Ganapathy-Kanniappan, 2020).”
Background
Cited by
Lactylation of METTL16 promotes cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer
Sun, L., Zhang, Y., Yang, B., Sun, S., Zhang, P., Luo, Z., Feng, T., Cui, Z., Zhu, T., Li, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42025-8 · Cited by 490
Metadata
- Authors
- Zhang, Z., Ma, Y., Guo, X., Du, Y., Zhu, Q., Wang, X., & Duan, C.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-10-08
- Volume
- 12
- Pages
- 749134-749134
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3206018533
- Cited by
- 180
- References
- 40
- FWCI
- 26.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.